Browsing by Author Ding, Lieming

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Showing results 1 to 7 of 7
Issue Date Title Author(s)
2017 BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus Ding, Lieming;Lu, Sisi;Wang, Yanping;Chen, Haibo;Long, Wei;Ma, Cunbo;He, Erlong;Yan, Dan;Tan, Fenlai
2018 BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1 Zhang, Panpan;Li, Shaolei;Lv, Chao;Si, Jiahui;Xiong, Ying;Ding, Lieming;Ma, Yuanyuan;Yang, Yue
2015 First-Line Icotinib Versus Cisplatine/Pemetrexed Plus Pemetrexed Maintenance in Advanced NSCLC Patients with EGFR Mutation Shi, Yuankai;Wang, Lin;Han, Baohui;Li, Wei;Yu, Ping;Liu, Yunpeng;Ding, Cuimin;Song, Xia;Ma, Zhiyong;Ren, Xinling;Feng, Jifeng;Zhang, Helong;Chen, Gongyan;Wu, Ning;Han, Xiaohong;Yao, Chen;Song, Yong;Zhang, Shucai;Ding, Lieming;Tan, Fenlai
20-May-2020 A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma. Si, Lu;Sheng, Xinan;Mao, Lili;Li, Caili;Wang, Xuan;Bai, Xue;Qi, Zhong Hui;Chi, Zhihong;Cui, Chuanliang;Lian, Bin;Tang, Bixia;Yan, Xieqiao;Zhou, Li;Li, Siming;Duan, Rong;Xu, Huayan;Mao, Li;Ding, Lieming;Guo, Jun
20-May-2021 A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer. Zhao, Jun;Li, Jianjie;Chen, Hanxiao;Yang, Xue;Zhong, Jia;Zhuo, Minglei;Jia, Bo;An, Tongtong;Wu, Meina;Wang, Ziping;Ding, Lieming;Mao, Li
2014 A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC) Hu, Xingsheng;Han, Baohui;Gu, Aiqin;Zhang, Yiping;Jiao, Shun Chang;Wang, Chang-li;He, Jintao;Jia, Xueke;Zhang, Li;Peng, Jiewen;Wu, Meina;Ying, Kejing;Wang, Junye;Ma, Kewei;Zhang, Shucai;You, Changxuan;Tan, Fenlai;Wang, Yinxiang;Ding, Lieming;Sun, Yan
Feb-2021 Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial Song, Yan;Wang, Jinwan;Ren, Xiubao;Jin, Jie;Mao, Li;Liang, Chris;Ding, Lieming;Yang, Lin